Go back to News
                NEWS
                GA_P advises Uriach on the sale of its generics and b2b business to MCH
Gómez-Acebo & Pombo has advised Grupo J. Uriach on the sale of its B2B business to the investment fund MCH, with the participation of a group of investors. With this transaction, Uriach completes the process of divestment in the pharmaceutical sector and sale of generics, to focus on its strategic business plan in the Consumer Healthcare (CHC) sector.
The divestment involves the sale of the two production plants owned by Grupo J. Uriach Group in Spain. On the one hand, the chemical plant (Urquima) located in Sant Fost de Campsentelles and the pharmaceutical plant in Palau-Solità i Plegamans, which currently allocates 75-80% of its production to the B2B business. The rest of this production is dedicated to CHC, which will continue to be made at this plant through a long-term strategic production agreement between Grupo J. Uriach and the new company owned by the new company. Uriach Group and the new company owned by MCH. This area has a forecast turnover of 80 million by the end of 2021. MCH’s objective is to expand its activity through new developments and R&D investment.
The sale agreement is currently subject to the approval of the competition authorities.
Lazard has been the bank advisor leading the transaction and Deloitte has acted as financial advisor.
The GA_P team was formed by Dani Marín, Carolina Posse, Estefanía Fraile and Diana Urrego, partner and associate, respectively, in the Corporate area, Iñigo Igartua and Andrea Díez de Uré, partner and associate in the Competition area, Nuria Vila, of counsel in the Tax area and Begoña Vilar, associate in the Employment area.
See complete article in Cinco Días
The divestment involves the sale of the two production plants owned by Grupo J. Uriach Group in Spain. On the one hand, the chemical plant (Urquima) located in Sant Fost de Campsentelles and the pharmaceutical plant in Palau-Solità i Plegamans, which currently allocates 75-80% of its production to the B2B business. The rest of this production is dedicated to CHC, which will continue to be made at this plant through a long-term strategic production agreement between Grupo J. Uriach and the new company owned by the new company. Uriach Group and the new company owned by MCH. This area has a forecast turnover of 80 million by the end of 2021. MCH’s objective is to expand its activity through new developments and R&D investment.
The sale agreement is currently subject to the approval of the competition authorities.
Lazard has been the bank advisor leading the transaction and Deloitte has acted as financial advisor.
The GA_P team was formed by Dani Marín, Carolina Posse, Estefanía Fraile and Diana Urrego, partner and associate, respectively, in the Corporate area, Iñigo Igartua and Andrea Díez de Uré, partner and associate in the Competition area, Nuria Vila, of counsel in the Tax area and Begoña Vilar, associate in the Employment area.
See complete article in Cinco Días
Lawyer mentioned
                    Daniel Marín – Partner
Carolina Posse Van Der Laat – Senior associate
See all lawyers
                        See less lawyers
                                    Category
                                    Deal
Press contact
 
            Sandra Cuesta
                        Director of Business Development, Marketing and Communications
                        
         
            Sandra Cuesta
                        Director of Business Development, Marketing and Communications
                        
        More information about
Gómez-Acebo & Pombo
        
            PUBLICATION        
        
             2 days ago
            2 days ago        
        
    
    
        
            Borderline products and the precedence of medicinal product legislation        
        
            The application of the rule of precedence requires, firstly, that a given product falls within the legal definition of a medicinal product, whether it is a medicinal product by function or by presentation, and secondly, that there are doubts as to whether it also falls within the legal concept of other types of products (food supplements, cosmetics, etc.).         
        
        
            PUBLICATION        
        
             17 Oct, 2025
            17 Oct, 2025        
        
    
    
        
            Impact on directors of company debts and penalties under a sector-specific rule        
        
            We analyse, in short, whether company payment contributions can be included in director liability (to company) claims.        
        
        
            PUBLICATION        
        
             01 Oct, 2025
            01 Oct, 2025        
        
    
    
        
            Contractual termination by mutual abandonment not claimed by any party?        
        
            The risks of applying the doctrine according to which a contract is deemed withdrawn from if neither party to the same appears to want it. Not only is this solution likely to be inconsistent with the parties' claims, but it also wrongly rules out other civil law options the parties could pursue upon dismissal of the action for declaration of termination.        
        
        
            PUBLICATION        
        
             25 Sep, 2025
            25 Sep, 2025        
        
    
    
        
            Pharma & Healthcare No. 45        
        
            The newsletter covers the main developments in Pharma & Healthcare legislation and case law.        
        
        
            PUBLICATION        
        
             05 Aug, 2025
            05 Aug, 2025        
        
    
    
        
            Automotive and Sustainable Mobility No. 27        
        
            Summary of legislative and jurisprudential developments relating to the automotive sector.        
        
        
            PUBLICATION        
        
             30 Jul, 2025
            30 Jul, 2025        
        
    
    
        
            Absolute prohibitions on pharmacy advertising are contrary to EU law        
        
            In its judgment of 19 June 2025 (European Commission v Republic of Poland, C‑200/24, ECLI:EU:C:2025:459), the Court of Justice has held that the introduction by national legislation of a total prohibition on advertising for pharmacies infringes European Union law.         
        
        
            PUBLICATION        
        
                    
        
             09 Jul, 2025
            09 Jul, 2025        
        
    
    
        
            Once again on the obligations assumed by the signers of a "strong" comfort letter        
        
        
            PUBLICATION        
        
             02 Jul, 2025
            02 Jul, 2025        
        
    
    
        
            Pharma & Healthcare No. 44        
        
            The newsletter covers the main developments in Pharma & Healthcare legislation and case law.        
        
        
            PUBLICATION        
        
             19 Jun, 2025
            19 Jun, 2025        
        
    
    
        
            Company resolutions reached with invalid votes        
        
            Although Article 204(3)(d) places them on the same level, the erroneous counting of votes and the counting of invalid votes are very different, given that the latter requires judicial balancing.